Benzinga | Dec 16, 2020 11:18AM EST

Berenberg Initiates Coverage On Spero Therapeutics with Buy Rating, Announces Price Target of $47

Berenberg analyst Esther Hong initiates coverage on Spero Therapeutics (NASDAQ:SPRO) with a Buy rating and announces Price Target of $47.